Loading...
01/11 04:07
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a mixed outlook. Positive aspects include growth in launched products, strategic partnerships, and promising pipeline developments. However, there are concerns about competitive pressures, revised gross margin outlook due to FX impacts, and lack of clarity in management's responses. The Q&A section highlights uncertainties in some areas, such as ENTYVIO's growth and competitive pressures. Overall, the sentiment is balanced between positive developments and potential risks, leading to a neutral prediction.
Revenue in H1 JPY 2.2 trillion, a decrease of 6.9% or minus 3.9% at constant exchange rates (CER). The decline was due to the loss of approximately JPY 100 billion of VYVANSE revenue.
Core Operating Profit (Core OP) JPY 639.2 billion, a year-on-year decrease of 11.2% at actual FX or 8.8% at CER. The decline was mainly due to the loss of exclusivity (LOE) of high-margin VYVANSE and a negative impact from transactional FX, which accounts for about 1/3 of the decline.
Reported Operating Profit JPY 253.6 billion, a decline of 27.7% due to larger impairment losses this fiscal year, including a JPY 58.2 billion expense related to the discontinuation of cell therapy efforts.
Core EPS JPY 279, reflecting a year-on-year decline. The decline was influenced by the loss of exclusivity of VYVANSE and transactional FX impacts.
Reported EPS JPY 72, a 40% decline year-on-year. This reflects the impairment of cell therapy, which is nondeductible from taxable income.
Adjusted Free Cash Flow JPY 525.4 billion, showing strong cash flow performance, including improvements in working capital.
Growth on Launch Products 5.3% at CER. This modest growth includes the impact of phasing of certain products, with higher growth anticipated in the second half.
ENTYVIO Growth 5.1% at CER. Growth was slightly below expectations due to slower-than-expected revenue growth, leading to a revised full-year forecast of 6% at CER.
TAKHZYRO Growth 5.9% at CER, continuing to grow steadily as a market leader in HAE prophylaxis.
PDT Portfolio Growth IG growth was 3.1%, with SCIG portfolio growing at double digits. Albumin declined slightly in H1 due to timing of shipments to China and cost containment measures, but high single-digit growth is expected for both IG and albumin in H2.
VYVANSE: Significant generic impact in H1 FY2025, with a revenue loss of approximately JPY 100 billion. Expected to have less impact moving forward.
ENTYVIO: Growth of 5.1% at constant exchange rate (CER) in H1 FY2025. Pen usage in the U.S. grew 20% quarter-to-quarter but represents only 9% of ENTYVIO volume. Full-year forecast revised to 6% growth at CER.
TAKHZYRO: Continues to grow steadily as a market leader in HAE prophylaxis with 5.9% growth at CER.
Rusfertide, Oveporexton, Zasocitinib: Three new product launches expected from FY2026 onwards. Positive Phase III studies for rusfertide and oveporexton, with zasocitinib Phase III data in psoriasis expected by the end of calendar year 2025.
Innovent Biologics Partnership: Strategic partnership to expand oncology pipeline with three differentiated assets: IBI363, IBI343, and IBI3001. Potential combined addressable market of over $48 billion.
QDENGA: Reallocated supply based on market needs, with some shipment timing pushed to later in FY2025. Transactional FX, particularly euro appreciation, impacted sales.
Operational Efficiencies: Efficiency improvements include organizational changes affecting 600 positions, real estate optimization, and R&D value chain efficiencies. Restructuring costs in H1 were JPY 27.4 billion.
Cost Discipline: Focused on driving OpEx savings to offset unfavorable product mix and FX impacts. Reduction in R&D and SG&A expenses contributed to mitigating profit decline.
Technology and AI: Leadership in leveraging technology and AI to transform the company.
Cell Therapy Discontinuation: Decision to discontinue cell therapy efforts, resulting in a JPY 58.2 billion impairment loss.
VYVANSE generic impact: The company faced a significant loss of approximately JPY 100 billion in revenue due to the loss of exclusivity (LOE) for VYVANSE, which has been a major headwind to growth.
Foreign exchange headwinds: Transactional foreign exchange, particularly the euro appreciation, has negatively impacted revenue and profits, especially for products like QDENGA.
Impairment losses: The company booked a nontax deductible impairment loss related to cell therapy discontinuation, which significantly impacted reported operating profit.
ENTYVIO growth challenges: ENTYVIO's revenue growth has been slightly below expectations, leading to a revised full-year forecast of 6% at constant exchange rates.
Medicare Part D redesign: This redesign has impacted several products in the U.S., including GAMMAGARD LIQUID, affecting revenue performance.
Albumin performance in China: Albumin sales declined slightly in H1 due to timing of shipments to China and cost containment measures, though performance is expected to improve in H2.
Operational efficiency challenges: The company is undergoing restructuring, including organizational changes affecting 600 positions and real estate optimization, to drive OpEx savings.
Oncology pipeline risks: The success of the oncology pipeline, including assets from the Innovent Biologics partnership, depends on clinical trial outcomes and regulatory approvals, which are inherently uncertain.
Revenue Expectations: Revenue in H1 was just over JPY 2.2 trillion, a decrease of 6.9% or minus 3.9% at constant exchange rates (CER). The company expects better growth rates for the full fiscal year, with growth and launch products delivering higher growth in H2 and VYVANSE year-on-year decline moderating.
Margin Projections: Core operating profit for H1 was JPY 639.2 billion, a year-on-year decrease of 11.2% at actual FX or 8.8% at CER. The company expects higher OpEx savings to fully mitigate the impact from unfavorable product mix, though transactional FX dynamics are expected to have a larger impact on profits.
Product Launches and Pipeline: From fiscal year 2026 onwards, Takeda anticipates three new product launches: rusfertide, oveporexton, and zasocitinib. The late-stage pipeline is expected to evolve further, supported by a strategic partnership with Innovent Biologics. The company plans to file for U.S. approval of oveporexton later this year and expects zasocitinib Phase III psoriasis data by the end of the calendar year.
Market Trends and Business Segment Performance: ENTYVIO growth is revised to 6% at CER for the full year. The PDT business is expected to grow at mid-single digits, with immunoglobulin and albumin growing at high single digits. Albumin performance is expected to accelerate in H2. The SCIG portfolio is growing at double digits and is expected to continue. Vaccines, including QDENGA, are expected to meet annual demand estimates despite timing shifts in shipments.
Operational Changes and Efficiency: The company is focused on cost discipline and operational efficiencies, including organizational changes impacting 600 positions and optimization of real estate. Restructuring costs in H1 were JPY 27.4 billion, with further OpEx savings expected.
Capital Expenditures and Financial Adjustments: The adjusted free cash flow forecast includes a USD 1.2 billion payment to Innovent Biologics for an in-licensing deal, funded by cash on hand. The dividend outlook remains JPY 200 per share for the full year.
Dividend Outlook: Our dividend outlook remains JPY 200 per share for the full year.
The earnings call highlights moderate impact from VYVANSE erosion, growth in launched products, and promising pipeline developments. Despite competitive pressures, ENTYVIO remains a leader. Takeda's strategic partnerships and debt management are positive. The Q&A reveals confidence in product developments and strategies to mitigate risks. Although some responses were vague, the overall sentiment is positive, supported by optimistic guidance and strategic growth plans.
The earnings call presents a mixed outlook. Positive aspects include growth in launched products, strategic partnerships, and promising pipeline developments. However, there are concerns about competitive pressures, revised gross margin outlook due to FX impacts, and lack of clarity in management's responses. The Q&A section highlights uncertainties in some areas, such as ENTYVIO's growth and competitive pressures. Overall, the sentiment is balanced between positive developments and potential risks, leading to a neutral prediction.
The earnings call presents mixed signals: while there is a dividend increase and optimistic guidance for product recovery, challenges like VYVANSE's revenue decline and unclear management responses on key issues temper positive sentiment. Adjustments in SG&A and R&D expenses due to FX and efficiency programs, and mixed product performance further contribute to a neutral outlook.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
